Effects of XRCC1 Polymorphism on Efficacy of Chemotherapy and Survival Time of Advanced Gastric Cancer Patients / 中国药房

ABSTRACT

OBJECTIVE:To investigate the effect of X-ray repair cross complementing gene(XRCC1)Arg399Gln(G→A) polymorphism on efficacy of oxaliplatin+fluorouracil chemotherapy and survival time of advanced gastric cancer patients. METH-ODSTotally 52 cases of advanced gastric cancer were selected from Hainan Provincial People's Hospital during Jan. 2013-Jan. 2015. They were given oxaliplatin+fluorouracil chemotherapy,for 3 courses(a treatment course lasted for 3 weeks). The genotypes of patients were detected by PCR-LDR. Disease control rate and progression free survival were compared among different geno-types. RESULTS:Among 52 cases of advanced gastric cancer,there were 28 cases of XRCC1 GG genotype(53.8%),21 cases of GA genotype(40.4%),3 cases of AA genotype(5.8%),frequencies of which were all in line with Hardy-Weinberg balance(P>0.05). Disease control rates of 52 cases were 76.9%,among which disease control rate(92.9%)of GG genotype was significantly higher than that of GA+AA genotype(58.3%),with statistical significance(P<0.05). The average progression free survival of 52 cases was(7.1+1.2)months,among which progression free survival of GG genotype [(8.6±0.8)months] was significantly longer than that of GG+GA genotype [(5.9 ± 0.7)months],with statistical significance (P<0.05). CONCLUSIONS:XRCC1 polymor-phism is correlated with efficacy of oxaliplatin+fluorouracil chemotherapy and progression free survival,and XRCC1 GG genotype is more sensitive to chemotherapy drugs. XRCC1 gene can be regarded as predictive indicator for therapeutic efficacy of chemothera-py and survival.